Clinical Trials Must Represent Those Who Will Receive Therapy
Whither CAR T? Will the FDA Being Under the Hood and the Availability of Bispecifics Make These Therapies Less Attractive?
Genetic Testing in Cancer Care: Considerations for a Condition-Based Approach